SCHEMBL14865164

SCHEMBL14865164

Cc1ccc(OC(C)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.46
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
TEAD4 Q15561 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
NLRP1 Q9C000 1/20 0.39
LMNA P02545 2/20 0.38
POLB P06746 2/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
RELA Q04206 1/20 0.37
ALDH1A3 P47895 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
PPARG P37231 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256789 0.82 LMNA (0.50) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL28771457 0.80 ALDH1A1 (0.48) ACHEKMT2AMEN1ALDH1A1MAPT
SCHEMBL29619678 0.80 ALDH1A1 (0.48) ACHEKMT2AMEN1ALDH1A1MAPT
SCHEMBL29619680 0.80 ALDH1A1 (0.48) ACHEKMT2AMEN1ALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL2441744 0.80 LMNA (0.49) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL104201 0.79 ALDH1A3 (0.54) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL1162019 0.79 ACHE (0.50) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL21868803 0.78 ACHE (0.44) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL12012135 0.78 TDP1 (0.48) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL2738300 0.78 MEN1 (0.39) KMT2AMEN1ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020230134-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed
EP-2895204-A1 COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS British Columbia Cancer Agency Branch (CA) 2015-07-22 EP disclosed
WO-2014040192-A1 COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2014-03-20 WO disclosed
EP-1994004-B9 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2013-04-17 EP disclosed